CXCR2--the receptor to hit?
- PMID: 17299604
- DOI: 10.1358/dnp.2006.19.10.1068009
CXCR2--the receptor to hit?
Abstract
Emigration of leukocytes from the microcirculation into inflammatory tissues is one of the hallmarks of our immune system. However, excessive leukocyte recruitment can disturb the integrity of the organism and aggravate acute and chronic inflammatory diseases. Chemokines are chemoattractant peptides that are used as messengers to direct leukocytes to sites of inflammation. They mediate their effects through G-protein-coupled chemokine receptors on the surface of leukocytes and other, nonhematopoietic cells, where they induce a variety of cell responses including cell activation and transmigration. CXC chemokine receptor 2 (CXCR2) has been implicated in numerous inflammatory disorders. In many models of acute and chronic inflammatory diseases, blockade of CXCR2 substantially reduces leukocyte recruitment, tissue damage and mortality. The physiological importance of CXCR2 has led to the development of selective CXCR2 inhibitors that are now being tested in clinical trials. This review will summarize current knowledge about CXCR2 in inflammatory diseases and discuss its potential as a pharmaceutical target.
Similar articles
-
CXCR2 blockade impairs angiotensin II-induced CC chemokine synthesis and mononuclear leukocyte infiltration.Arterioscler Thromb Vasc Biol. 2007 Nov;27(11):2370-6. doi: 10.1161/ATVBAHA.107.147009. Epub 2007 Aug 23. Arterioscler Thromb Vasc Biol. 2007. PMID: 17717298
-
CXCR2 antagonists for the treatment of pulmonary disease.Pharmacol Ther. 2009 Jan;121(1):55-68. doi: 10.1016/j.pharmthera.2008.10.005. Epub 2008 Oct 31. Pharmacol Ther. 2009. PMID: 19026683 Review.
-
ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.Pharmacol Ther. 2006 Oct;112(1):139-49. doi: 10.1016/j.pharmthera.2006.04.002. Epub 2006 May 23. Pharmacol Ther. 2006. PMID: 16720046 Review.
-
Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment.Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16278-83. doi: 10.1073/pnas.0804017105. Epub 2008 Oct 13. Proc Natl Acad Sci U S A. 2008. PMID: 18852457 Free PMC article.
-
CXCR2 inhibition suppresses hemorrhage-induced priming for acute lung injury in mice.J Leukoc Biol. 2004 Jul;76(1):58-64. doi: 10.1189/jlb.1103541. Epub 2004 May 3. J Leukoc Biol. 2004. PMID: 15123771
Cited by
-
Potential evidence for biotype-specific chemokine profile following BVDV infection of bovine macrophages.Vet Immunol Immunopathol. 2012 Nov 15;150(1-2):123-7. doi: 10.1016/j.vetimm.2012.08.009. Epub 2012 Sep 1. Vet Immunol Immunopathol. 2012. PMID: 22985634 Free PMC article.
-
CXCR2: From Bench to Bedside.Front Immunol. 2012 Aug 24;3:263. doi: 10.3389/fimmu.2012.00263. eCollection 2012. Front Immunol. 2012. PMID: 22936934 Free PMC article.
-
Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.J Cereb Blood Flow Metab. 2010 Mar;30(3):459-73. doi: 10.1038/jcbfm.2009.240. Epub 2009 Nov 11. J Cereb Blood Flow Metab. 2010. PMID: 19904283 Free PMC article. Review.
-
Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology.Immunity. 2009 Nov 20;31(5):711-21. doi: 10.1016/j.immuni.2009.09.010. Immunity. 2009. PMID: 19836265 Free PMC article. Review.
-
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.Sci Transl Med. 2014 May 21;6(237):237ra67. doi: 10.1126/scitranslmed.3007974. Sci Transl Med. 2014. PMID: 24848257 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
